This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephen R. Thomas, PharmD
Family Physicians Association of Flower Hospital Sylvania, Ohio

JAMA. 1997;277(10):788.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Grossman and colleagues¹ regarding the 1985 review by the Cardiorenal Advisory Committee of the Food and Drug Administration (FDA) of sublingual nifedipine is food for thought, but does little to convince the reader that this medication does not have a place in modern-day pharmacotherapy. If one considers the presented review of antihypertensive efficacy of nifedipine and examines the references pertaining to efficacy, it is evident that 21 of these references were published after 1985. This raises the question, if the FDA had this information in 1985, would it have come to a different conclusion concerning shortacting nifedipine use in hypertensive emergencies?

Beyond encouraging discontinuation of the sublingual dosing method for nifedipine, the value of the article by Grossman et al appears to be its review of patient risk factors for developing a hypotensive episode with nifedipine. It would be prudent to avoid using short-acting nifedipine . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?